Seattle genetics says fda accepts priority review of tucatinib new drug application

Seattle genetics announces fda filing acceptance for priority review of tucatinib new drug application (nda) for patients with locally advanced or metastatic her2-positive breast cancer.seattle genetics inc - under prescription drug user fee act (pdufa), fda has set a target action date of august 20, 2020 for tucatinib.
SGEN Ratings Summary
SGEN Quant Ranking